



24 July 2018

Company Announcements Office
Australian Securities Exchange
20 Bridge Street
SYDNEY NSW 2000

Dear Sir/Madam

NOTICE UNDER SECTION 708A OF THE CORPORATIONS ACT

This notice is given by Actinogen Medical Limited pursuant to section 708A(5)(e) of the Corporations Act (**ACT**).

On 12 July 2018, the Company issued 11,200,000 fully paid ordinary shares at an issue price of \$0.05 per share (the **Securities**), in accordance with the placement under the Share Purchase Plan Shortfall announced to the market on 17 July 2018.

In accordance with section 708A(5)(e) of the Act, the Company gives notice that:

1. the Company issued the Securities without disclosure to investors under part 6D.2 of the Act;
2. as at the date of this notice the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company and section 674 of the Act; and
3. as at the date of this notice there is no information:
 - a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;
 - b. that investors and their professional advisers would reasonably require for the purposes of making an informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - ii. the rights and liabilities attaching to the Securities.

Yours faithfully

A handwritten signature in black ink, appearing to read "Peter Webse", is written over a faint, light grey circular stamp.

Peter Webse
Company Secretary